Interview: Prof. Dr. Murat Özgören – Vice-Rector, Dokuz Eylül…
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
Dokuz Eylül Health Technopark DEPARK
The first thematic health technopark in Turkey that is fully integrated with hospital, research centers and medical schools. It is an ideal location for biotech and medical device companies inb Turkey for R&D, product development and soft-landing. DEPARK has started medical technopark services at its mother building ZEYTIN. The name zeytin refers to olives and it stands for 3500 years lifespan of olive trees while still producing olives. It also refers to natural health remedies that are attached to the olive (e.g. as in the movie Lorenzo’s Oil). There is a specifically medicine oriented technology transfer office called DETTO (Dokuz Eylül Technology Transfer Office). It has a wide variety of services from international soft landing, tax and law support, IP rights management, incubation, technical consultancy, funding, clinical trials, pre-clinical consultation to marketing and guidance for international partnering. The hosting university, Dokuz Eylül University, has 14 faculties (app 67,000 students) to support the larger ecosystem for a wide range of activities and research. The ecosystem includes a university hospital over 1,100 beds, medical school, medical graduate study programs, medical research institutes (ie oncology, genome etc), nearly 1,000 academics, health technologies accelerator, associate service study programs like nursing, health technicians, sports technologies, physiotherapy center, medical devices calibration center and home-care research center.
BioIzmir
BioIzmir is an international gateway project for creating a one-stop-shop ecosystem for biotech and medical devices. It is located within a health technopark (DEPARK) embedded into a hospital complex.
From design to manufacturing, process to IPR rights this will be a critical partner for companies and development/tech transfer organizations. Izmir Health Technologies Development and Accelerator Center will serve as a hub of the essential elements known in medical circle as “from the laboratory bench to the patient’s bedside”. The structure of the Center will provide “one-stop-shop” aimed to establish Izmir as the intersection of health enterprise and innovation in regional, national and international contexts. The activities within the scope of the project will create an eco system in which integration occurs between the industry and the dynamics of R&D and innovation.
iBG-izmir
Dokuz Eylul University Izmir Biomedicine and Genome Center (iBG-izmir) is developed within “Bioİzmir” Science and Technology Park, which is the result of the innovative partnership of DEU Health Campus, the Faculty of Medicine & University Hospital and the Health Themed Technopark (DEPARK). iBG is the first such regional hub, with headquarters in Izmir, Turkey’s third largest city and a critical locomotive for growing Turkish economy, particularly within the health sector. iBG’s vision is to establish a most prominent center for health and life sicences in South-West Europe and MENA countries in a 10 years period. This comprehensive regional hub will be multidisciplinary in approach and shall bring molecular biology, genetics, medicine, pharmaceutical sciences, bioengineering, computer engineering and many other fields together. iBG-izmir will open its doors in 09-10 Sep 2015 with including Nobel session and reception.
Contact
Dokuz Eylül Üniversitesi İnciraltı Yerleşkesi Balçova
35340 İzmir Türkiye
Tel: +90 (232) 412 80 00
Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the…
PharmaBoardroom talked to Sr. Managing Director of Medtronic Turkey, Ayhan Ozturk about improving patient outcomes, how the company introduced a whole new standard on integrated healthcare, and their recent USD $25 million…
Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also…
Sevi Firat, Founding Partner of Firat Izgi discusses the legal challenges facing pharmaceutical companies looking to penetrate the healthcare market in Turkey, the evolution of the legal landscape and her…
Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over…
A founding partner of YükselKarkınKüçük, Gökhan Gökçe discusses the firm’s involvement with several high profile cases concerning the healthcare and life science sector’s reference pricing system, and also elaborates on…
The managing director of DHL Express Turkey, Markus Reckling highlights the strategic importance of Turkey to the global DHL Express portfolio and elaborates on the market opportunities present for DHL’s…
The co-founder of Ekin Kimya discusses the need for greater regulation and monitoring of raw materials used in Turkish pharmaceutical manufacturing, his company’s key role as an educator and advisor…
Novartis country president Peter Catalino discusses the need for Turkey to introduce financial investment incentives to compete more effectively with other countries for investments in R&D and manufacturing. You arrived…
The chairman and CEO of Santa Farma discusses how the Turkish pharmaceutical landscape has evolved in response to the government’s healthcare transformation programs. He also enumerates various strategic initiatives the…
Omega CRO has evolved from its beginnings as a CRO contracted by local and multinational pharmaceutical companies into an organization leading clinical, epidemiological and observational studies of public interest across…
The president of the Turkish Drug and Medical Device Agency (TITCK) discusses new initiatives and reforms being carried out by his agency, including its work towards becoming a PIC/s member, and…
The CEO of Centurion shares his ambitious vision for the company’s expansion into plasma products, biotech, orphan drugs, and generic injectables over the coming years, while simultaneously developing sales in more than…
See our Cookie Privacy Policy Here